Can-Fite BioPharma’s (CANF) “Buy” Rating Reiterated at D. Boral Capital

D. Boral Capital reaffirmed their buy rating on shares of Can-Fite BioPharma (NYSE:CANF) in a research report sent to investors on Tuesday morning,Benzinga reports. The brokerage currently has a $11.00 target price on the stock.

Can-Fite BioPharma Price Performance

NYSE:CANF opened at $0.65 on Tuesday. The firm’s 50-day moving average price is $0.74 and its 200-day moving average price is $1.07. The company has a market capitalization of $2.30 million, a PE ratio of -0.36 and a beta of 1.06. Can-Fite BioPharma has a 1-year low of $0.63 and a 1-year high of $3.12.

Hedge Funds Weigh In On Can-Fite BioPharma

A hedge fund recently bought a new stake in Can-Fite BioPharma stock. BNP Paribas Financial Markets bought a new stake in shares of Can-Fite BioPharma Ltd. (NYSE:CANF) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 25,185 shares of the company’s stock, valued at approximately $41,000. BNP Paribas Financial Markets owned 0.71% of Can-Fite BioPharma as of its most recent filing with the Securities and Exchange Commission. 21.00% of the stock is owned by institutional investors.

About Can-Fite BioPharma

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.